AstraZeneca Vaccine Shows Efficacy of Up to 90%
Nov 23 2020 · 11:03 UTC by John K. Kumi · 3 min read
Photo: Depositphotos
One of the regimens came out with 62% efficacy when administered for one month apart in two full doses. The other dosing regimen came out with an efficacy rate of 90% when administered for at least a month apart with a half dose followed by a full dose.
The COVID-19 vaccine being developed by AstraZeneca Plc (LON: AZN) in collaboration with the University of Oxford has appeared to have an efficacy of up to 90%. The last stage of the AstraZeneca vaccine trial was conducted in the UK and Brazil and is continuing in the US. According to the reports, it underwent two separate dosing regimens. One of the regimens came out with 62% efficacy when administered for one month apart in two full doses. The other dosing regimen came out with an efficacy rate of 90% when administered for at least a month apart with a half dose followed by a full dose. This means it has an average efficacy of 70%.
According to the Chief Investigator of the Oxford Vaccine Trial Professor Andrew Pollard, the results of the conducted trials indicates that they currently have a working vaccine that when applied can save many lives. Pollard explains that since one of their dosing regimens came out with an effective rate of 90%, more people could be vaccinated with that dosing regimen when an effective planned vaccine supply is carried out. He revealed that they will soon start the process of preparing a regulatory submission of data to authorities that have early approval or conditional approvals in such cases.
COVID-19 has claimed more than 1 million lives, and according to the CEO of AstraZeneca Pascal Soriot, this development is an important milestone in the fight against the global pandemic. The results of the AstraZeneca Vaccine trials comes as good news following the recent positive development announced by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA).
It is worth noting that the AstraZeneca vaccine results did not come with a serious side effect or a safety event as both dosing regimens came out good. Soriot hinted that once the AstraZeneca Vaccine is approved, it would be made globally available and affordable to serve hundreds of millions of people. This is to satisfy their pledge of not prioritizing profits, but stay committed and ensure equitable and timely access.
Britain Accepts AstraZeneca COVID-19 Vaccine in Open Arms
Matt Hancock, the British Health Secretary received this news with a lot of excitement revealing that they have already made 100 million pre-orders, and once that goes well, they will go all out in the new year. Hancock also stated that regulators would need to consider whether the program that leads to the administration of the AstraZeneca COVID-19 vaccine to get the 90% efficacy is the appropriate way.
Having said that, Hancock stated that there is evidence in the report that establishes that the AstraZeneca Vaccine cannot only prevent people from contracting the virus but can also reduce the transmission. This follows the hint that people who got the regime with higher protection had a good chance of minimizing asymptomatic infections. He added that this is good news If confirmed to be true.
The UK has already ordered 40 million of the Pfizer and BioNtech vaccine that has shown the efficacy of 95%.
next Business News, Editor's Choice, Market News, News
Author John K. Kumi
Excellent John K. Kumi is a cryptocurrency and fintech enthusiast, operations manager of a fintech platform, writer, researcher, and a huge fan of creative writing. With an Economics background, he finds much interest in the invisible factors that causes price change in anything measured with valuation. He has been in the crypto/blockchain space in the last five (5) years. He mostly watches football highlights and movies in his free time.
By Tolu Ajiboye December 31st, 2022
Blockchain News, Business News, Cryptocurrency news, Market News, News 2022 in Review: Top 15 Stories of the Year
As the year winds down and we anticipate 2023, Coinspeaker has put together a recap of some of the most newsworthy events of 2022.
By Tolu Ajiboye October 28th, 2022
Business News, Market News, News, Stocks, Story of the Day Meta Drops Out of Top 20 Most Valuable Companies amid Sustained Facebook Slip Up
The dwindling fortunes of Facebook has seen parent company Meta lose its position as one of the US top 20 companies ranked by market cap.
Business News, Market News, News, Stocks, Wall Street Johnson & Johnson Q3 2022 Report Beat Estimates as Hospital Staffing Problem Resolves
Johnson & Johnson saw a better-than-expected in the third quarter according to its Q3 2022 report. However, JNJ may cut jobs soon.
British Finance Minister Calls on Tech Giants to Stoke Growth in Nation amid Reformative Tax Hikes
Bitcoin Back Above $23,000 Once Again, Altcoins Support Rally
Nasdaq Sees Lower Close for Second Day amid Corporate Earnings Season
Dow Futures Ink Slight Gains as Investors Digest Corporate Earnings Result
Bitcoin (BTC) on 2-Day Losing Streak as Broader Tech Sector Takes Plunge
Real Estate Token (REST)
The most realistic Platform based on Blockchain and Real Estate
Submit Your IEO
Submit Your STO